

PharmaMar to host Conference Call and Webcast on Wednesday, January 4th, 2017 to discuss the License and Commercialization agreement with Chugai Pharmaceuticals for Lurbinectedin in Japan

PharmaMar to receive an upfront payment of €30 million plus milestones and royalties

Madrid, January 3, 2017 – PharmaMar (MSE:PHM) announced today that senior management will host a conference call tomorrow, Wednesday, January 4, 2017 at 8:00 am ET (2:00 pm CET) to discuss the company's recent announcement regarding the exclusive license, development and commercialization agreement with Chugai Pharmaceutical Co. Ltd. (TSE:4519) for its third marine-derived anticancer drug PM1183 (lurbinectedin) in Japan.

As previously reported, under the terms of the agreement PharmaMar will receive an upfront payment of €30 million, along with double-digit tiered royalties, and will also be eligible for receiving payments in line with the progress of the development and sales milestones; potentially worth over €100 million. PharmaMar will continue to conduct the clinical development activities for the first two indications of PM1183 in Japan, whereas Chugai will make milestone payments at study initiation, be responsible for registration filing and will also have the rights to conduct clinical development in Japan to pursue additional indications.

Investors who wish to participate in the conference call may do so by dialing 877-407-3102 for U.S. and Canadian callers or 201-493-6790 for international callers and 900 834 236 for Spain. Those interested in listening to the conference call via the internet may do so by visiting the [Events Calendar](#) page of the company's website at www.pharmamar.com and clicking on the webcast link.

A webcast replay will be available on the PharmaMar website for 30 days following the call by visiting the [Events Calendar](#) page of the company's website at www.pharmamar.com.

About PM1183 (lurbinectedin)

PM1183 is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction. The

antitumor efficacy of lurbinectedin is being investigated in various types of solid tumors, including a Phase III study for platinum-resistant ovarian cancer, a Phase II study for BRCA 1 and BRCA 2-associated metastatic breast cancer and a Phase III study for small cell lung cancer.

About Chugai Pharmaceutical Co. Ltd.

Chugai Pharmaceutical is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area. In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai's proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe. The consolidated revenue in 2015 of Chugai totaled 498.8 billion yen and the operating income was 90.7 billion yen (IFRS Core basis). Additional information is available on the internet at <http://www.chugai-pharm.co.jp/english>.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127

Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215

Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com